Immunocore Holdings (IMCR) Investor Presentation - Slideshow

KIMMTRAK (Tebentafusp) Achievements and Commercial Launch - KIMMTRAK received FDA approval as the first TCR therapeutic for metastatic uveal melanoma (mUM)[10, 61] - KIMMTRAK is the first T-cell engager to demonstrate an Overall Survival (OS) benefit in solid tumors[61] - KIMMTRAK has been approved in over 30 countries, including the US, UK, EU, Australia, and Canada[10, 62, 70] - Immunocore reported $465 million in KIMMTRAK net revenue for the first half of 2022[62] - In the US, over 60% of patients are now receiving KIMMTRAK as a first-line treatment[64] Clinical Trial Updates and Pipeline - A Phase 2/3 study of Tebentafusp for previously treated advanced melanoma patients is expected to begin in Q4 2022[10, 23, 24] - Phase 1 data for IMC-F106C (targeting PRAME) was presented at ESMO, with expansion arms initiated for cutaneous melanoma, ovarian, NSCLC, and endometrial cancers[10] - Initial Phase 1 data for IMC-I109V (targeting Hepatitis B Virus) was presented at EASL[10] - Phase 1 trial of IMC-M113V (targeting HIV) has been initiated in 2022[10, 60] PRAME and MAGE-A4 Programs - IMC-F106C demonstrated strong and consistent pharmacodynamic activity at doses ≥20 mcg[31] - Responses were observed in multiple tumor types in the IMC-F106C PRAME Phase 1 study, including cutaneous melanoma, uveal melanoma, ovarian cancer, endometrial cancer and NSCLC[36] - Reduction in circulating tumor DNA (ctDNA) was observed across tumor types in the IMC-F106C study, with 90% showing any reduction[40]